Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains

Molecular Neurodegeneration

Volumn 11, Issue 1, 2016, Pages 1-9

  Ma, Li ^a   Allen, Mariet ^a   Sakae, Nobutaka ^a   Ertekin Taner, Nilufer ^a,b   Graff Radford, Neill R ^b   Dickson, Dennis W ^a   Younkin, Steven G ^a   Sevlever, Daniel ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

AD; Microglia; R47H; TREM2

Indexed keywords

HYDROLASE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TRANSCRIPTOME; TREM2 PROTEIN, HUMAN;

AGED; ALLELE; ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GLYCOSYLATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TEMPORAL CORTEX; TREM2 GENE; VERY ELDERLY; WESTERN BLOTTING; WILD TYPE; BRAIN; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENETICS; METABOLISM;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ALZHEIMER DISEASE; BLOTTING, WESTERN; BRAIN; FEMALE; GENE EXPRESSION PROFILING; GENETIC VARIATION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; TRANSCRIPTOME;

EID: 84997294866     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-016-0137-9     Document Type: Article

References (19)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-6.
2. Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov Alexei A, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153(3):707-20.
3. Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094-9.
4. Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-41.
5. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-27. PMCID: 3631573.
6. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2):107-16. PMCID: 3677583.
7. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7(12):1266-73.
8. Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25(3):357-61.
9. Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med. 2003;198(4):669-75. PMCID: 2194176.
10. Thrash JC, Torbett BE, Carson MJ. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem Res. 2009;34(1):38-45. PMCID: 2655126.
11. Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem. 2013;288(46):33027-36. PMCID: 3829152.
12. Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131(11):3081-91.
13. Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet. 2014;23(21):5838-46. PMCID: 4189899.
14. Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86.
15. Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, et al. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener. 2015;10:19. PMCID: 4426167.
16. Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;3(6):925-33.
17. Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG. TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 2015;25(4):469-80. PMCID: 4427527.
18. Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimers Dement. 2015;11(10):1163-70. PMCID: 4461564.
19. Park J-S, Ji IJ, An HJ, Kang M-J, Kang S-W, Kim D-H, et al. Disease-associated mutations of TREM2 Alter the processing of N-linked oligosaccharides in the golgi apparatus. Traffic. 2015;16(5):510-8.